Brilinta not significantly better than aspirin in stroke

AstraZeneca plc (LSE:AZN; NYSE:AZN) said Brilinta ticagrelor missed the primary endpoint in the global Phase III SOCRATES trial. The anticoagulant failed to significantly prevent major vascular events in patients with acute ischemic stroke or transient ischemic attack (TIA).

The primary endpoint was time to first occurrence of stroke, myocardial infarction (MI) or death. AstraZeneca said there were fewer events among patients who received 90 mg twice-daily Brilinta for 90 days vs. aspirin, but the difference was not significant. ...